Drug manufacturer Piramal Life Sciences has started the first phase trial of a new experimental drug molecule ‘P2202’ in Canada.
 
The company has already bagged the approval from Health Canada for the trial.

Piramal Life Sciences said, “The company has commenced phase I trail of a new experimental drug molecule P2202 for diabetes-metabolic syndrome in Canada.”

According to the company, P2202 is the second compound from US-based Eli Lilly Co, and is part of the joint agreement which it signed with it to develop the diabetes-metabolic drugs.

P2202 is being developed in order to cure metabolic disorders. Its initial dosage on animals exposed lower glucose levels, triglycerides, and total cholesterol as also decrease in plaque in animals suffering from atherosclerosis.

Swati Piramal, Piramal Group Director said, “We are dedicated to finding new cures for metabolic disorders.”

The phase I study of P2202 in fit volunteers has been started to set up the safety, tolerability pharmacokinetics and pharmacodynamics of the remedy.

Mr. Somesh Sharma, Piramal Managing Director, said, “This is our eighth entity to enter the clinic and third for diabetes-metabolic disorders and bears testimony to our efforts to build a diversified and strong pipeline of products to address unmet medical needs in this important therapeutic segment.”

At 10:02 a.m., the shares of the company gained 5% to trade at Rs 63.35 at the BSE.